Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans
about
Valsartan and retinal endothelial function in elderly hypertensive patients.DDSolver: an add-in program for modeling and comparison of drug dissolution profiles.Sympathetic activation and nitric oxide function in early hypertension.Reduction in alpha-adrenergic receptor-mediated vascular tone contributes to improved arterial compliance with endurance training.Nitric oxide synthase inhibitors in cardiogenic shock: present and future.Inhibition of nitric oxide synthases prevents and reverses alpha,beta-meATP-induced neck muscle nociception in mice.Contribution of nitric oxide to the blood pressure and arterial responses to exercise in humans.Removal of tonic nitrergic inhibition is a potent stimulus for human proximal colonic propagating sequences.Cardiovascular effects of vasopressin following V(1) receptor blockade compared to effects of nitroglycerin.Exploration of statistical experimental design to improve entrapment efficiency of acyclovir in poly (d, l) lactide nanoparticles.Contributions of nitric oxide synthase isozymes to exhaled nitric oxide and hypoxic pulmonary vasoconstriction in rabbit lungs.Inhibition of nitric oxide synthase does not alter dynamic cerebral autoregulation in humans.Increased response of renal perfusion to the antioxidant vitamin C in type 2 diabetes.Combined treatment with a nonselective nitric oxide synthase inhibitor (l-NMMA) and indomethacin increases ductus constriction in extremely premature newborns.Systemic alpha-adrenergic and nitric oxide inhibition on basal limb blood flow: effects of endurance training in middle-aged and older adults.Relationship between muscle sympathetic nerve activity and systemic hemodynamics during nitric oxide synthase inhibition in humans.Nitric oxide regulation of migrating motor complex: randomized trial of N(G)-monomethyl-L-arginine effects in relation to muscarinic and serotonergic receptor blockade.Potentiation of the NO-cGMP pathway and blood flow responses during dynamic exercise in healthy humans.
P2860
Q33251603-9C9A33C5-24E1-4242-B348-5895FF3CFD80Q33550419-CCF7DDB1-5E30-4F8F-A39C-940FDD4CA355Q35900912-87E78D8F-85AF-40FE-B645-224CCAB2533BQ37350703-3B58451F-BCD9-477D-BE85-5B512A264697Q37608590-C58F0CAB-5796-401E-B7C4-BA8BDC3A91FEQ39835673-37D266D3-578F-45A3-A37B-ADAAEAD1ABCEQ39869243-42D17D83-E514-489B-A016-EF70A4808BBEQ43330204-5D9FB6DA-2E46-4353-962F-14FF9BA3FD04Q43708490-B7CD0659-C64D-46FA-96B9-F82815B857DAQ43804494-FD40F23C-3F50-41FF-8667-7F23762D407CQ44281818-E0DA0826-38CF-47A5-AA5A-A8674B00609CQ44791351-7D0478EC-70E3-4721-A733-4FDF6B28C5A5Q44987597-1BAEEBC5-C2B3-4DC9-B919-FEC667701882Q46782595-77A86ED0-98E9-4A12-B21E-E3A6A87E3AAAQ51006914-3976D70C-6293-4401-99EE-896A9D639C34Q51214305-7BC5ACE4-4AEA-4FB6-9816-97FDA81B7BAFQ51299957-826967F5-5A24-4021-9420-473ED487B126Q53539695-E28AF83F-6571-4742-8AB9-BE40C8503D72
P2860
Pharmacokinetic-pharmacodynamic profile of systemic nitric oxide-synthase inhibition with L-NMMA in humans
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh
1999年學術文章
@zh-hant
name
Pharmacokinetic-pharmacodynami ...... hibition with L-NMMA in humans
@ast
Pharmacokinetic-pharmacodynami ...... hibition with L-NMMA in humans
@en
type
label
Pharmacokinetic-pharmacodynami ...... hibition with L-NMMA in humans
@ast
Pharmacokinetic-pharmacodynami ...... hibition with L-NMMA in humans
@en
prefLabel
Pharmacokinetic-pharmacodynami ...... hibition with L-NMMA in humans
@ast
Pharmacokinetic-pharmacodynami ...... hibition with L-NMMA in humans
@en
P2093
P2860
P1476
Pharmacokinetic-pharmacodynami ...... hibition with L-NMMA in humans
@en
P2093
H Derendorf
H G Eichler
L Schmetterer
S Krishnaswami
P2860
P304
P356
10.1046/J.1365-2125.1999.00930.X
P407
P577
1999-05-01T00:00:00Z